Abstract: PO0056
COVID-19 Among Hospitalized Patients with Kidney Disease: Experience at a Midwestern Medical Center
Session Information
- COVID-19: Epidemiology, Outcomes, Complications, and Risk Factors
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Lentine, Krista L., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Pahlavani, Seyedmahdi, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Caliskan, Yasar, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Schnell, Ariel A., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Marino, Nikolas Evan, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Taylor, Aberdeen X., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Elewa, Usama, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Philipneri, Marie D., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Mosman, Amy, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Vo, Thanh-Mai Nguyen, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Ouseph, Rosemary, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Ainapurapu, Sruthi, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
- Groll, Thomas Richard, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
Background
Manifestations of novel coronavirus disease-2019 (COVID-19) range from minimal symptoms to organ failure and death. Preliminary studies suggest that acute kidney injury (AKI) is a common complication of COVID-19 and may predict adverse outcomes. Patients with chronic kidney diseases may be vulnerable to increased risk of serious COVID-19-related complications.
Methods
In this (ongoing) retrospective cohort study, we examined the characteristics, presentations, treatments, and outcomes of COVID-19 among hospitalized patients with AKI, dialysis-dependent end-stage kidney disease (ESKD-D) or kidney transplantation (KTx) at an urban, Midwestern tertiary center (3/19/2021–3/25/2021).
Results
Among 184 patients, 91 had AKI (49%), 51 CKD5-D (28%), and 42 patients were KTx recipients (23%). Monthly cases ranged from 6 in March to 35 patients in December 2020. Among the cohort, 61% were Black (including 50% AKI, 82% ESKD-D, and 57% KTx). Overall, 35% required mechanical ventilation, with highest use in the AKI group (51%). 48% of AKI patients required renal replacement therapy (RRT) and 9% treated with ECMO. Mechanical ventilation was lower among KTx recipients (12%) and 9% required RRT. The most common medical treatment was dexamethasone (48%). Mortality was 46% in the AKI and 23% in CKD5-D groups, but 2% among KTx recipients.
Conclusion
We observed high mortality associated with COVID-19 among hospitalized patients with kidney disease, especially in those with AKI. Public health and therapeutic studies should focus on mitigating COVID-19 disease transmission and optimizing outcomes in this vulnerable population.
Cohort Characteristics and Key Outcomes